Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Octreotide Acetate

FDA-approved product (injectable, injection), marketed as Bynfezia Pen, Mycapssa, Octreotide Acetate and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Octreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid tumor
  • Metastasis
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
FDA pharmacologic class
Somatostatin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Octreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Octreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Angiotensin 2 for Hepatorenal Syndrome

    NCT04048707 · start 2021-07-01

    Registered record
    Registry ID
    NCT04048707
    Conditions
    Hepatorenal Syndrome; Cirrhosis; Kidney Failure, Acute
    Interventions
    Angiotensin II; Midodrine; Octreotide; Albumin solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2021-07-01
    Completion
    2023-07-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome; Cirrhosis; Kidney Failure, Acute
    InterventionAngiotensin II; Midodrine; Octreotide; Albumin solution
    PhasePhase 2
    Registry statusWithdrawn

  • Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

    NCT04997317 · start 2021-04-21

    Registered record
    Registry ID
    NCT04997317
    Conditions
    Meningioma
    Interventions
    177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over); 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4; 177Lu-DOTA-JR11 (Phase I/II)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2021-04-21
    Completion
    2026-12-31
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningioma
    Intervention177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over); 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4 +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

    NCT05683444 · start 2020-07-01

    Registered record
    Registry ID
    NCT05683444
    Conditions
    Lymphatic Diseases; Chylothorax
    Interventions
    Octreotide infusion; Saline infusion
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2021-03-26
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Diseases; Chylothorax
    InterventionOctreotide infusion; Saline infusion
    PhaseEarly phase 1
    Registry statusCompleted

  • A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

    NCT03057509 · start 2018-11

    Registered record
    Registry ID
    NCT03057509
    Conditions
    Small Bowel Carcinoid Tumor
    Interventions
    Ga-68-DOTA-TOC; Siemens PET/MR scanner; Standard Siemens Software; LAR Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2018-11
    Completion
    2021-09-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Bowel Carcinoid Tumor
    InterventionGa-68-DOTA-TOC; Siemens PET/MR scanner; Standard Siemens Software; LAR Octreotide
    PhasePhase 1
    Registry statusWithdrawn

  • The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

    NCT03158090 · start 2017-12-15

    Registered record
    Registry ID
    NCT03158090
    Conditions
    Acromegaly
    Interventions
    Transnasal butterfly surgery; sandostatin; radiotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2017-12-15
    Completion
    2051-01-30
    Enrolment
    1,965

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionTransnasal butterfly surgery; sandostatin; radiotherapy
    PhaseNot recorded
    Registry statusRecruiting

  • Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

    NCT03197012 · start 2017-07-01

    Registered record
    Registry ID
    NCT03197012
    Conditions
    Neuroendocrine Tumor
    Interventions
    90Y-DOTA-TOC; 68Ga-DOTA-TOC
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-07-01
    Completion
    2019-05-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumor
    Intervention90Y-DOTA-TOC; 68Ga-DOTA-TOC
    PhaseEarly phase 1
    Registry statusCompleted

  • Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery

    NCT02437825 · start 2015-10

    Registered record
    Registry ID
    NCT02437825
    Conditions
    Fistula; Salivary Duct or Gland
    Interventions
    octreotide; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2021-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFistula; Salivary Duct or Gland
    Interventionoctreotide; placebo
    PhasePhase 2
    Registry statusUnknown

  • Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

    NCT02299089 · start 2015-01

    Registered record
    Registry ID
    NCT02299089
    Conditions
    Acromegaly; Neuroendocrine Tumors
    Interventions
    octreotide FluidCrystal® injection depot
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly; Neuroendocrine Tumors
    Interventionoctreotide FluidCrystal® injection depot
    PhasePhase 2
    Registry statusCompleted

  • GA-68 DOTA-TOC of Somatostatin Positive Malignancies

    NCT02177773 · start 2014-06-23

    Registered record
    Registry ID
    NCT02177773
    Conditions
    Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors; Neuroblastoma
    Interventions
    Computed Tomography (CT); Gallium Ga 68-Edotreotide; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2014-06-23
    Completion
    2017-08-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroendocrine Tumor; Paraganglioma; Carcinoid Tumors; Neuroblastoma
    InterventionComputed Tomography (CT); Gallium Ga 68-Edotreotide; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET)
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

    NCT02294006 · start 2014-06

    Registered record
    Registry ID
    NCT02294006
    Conditions
    Well Differentiated Pancreatic Endocrine Tumor
    Interventions
    Everolimus plus Octreotide LAR plus Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2021-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWell Differentiated Pancreatic Endocrine Tumor
    InterventionEverolimus plus Octreotide LAR plus Metformin
    PhasePhase 2
    Registry statusUnknown

  • Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

    NCT02474914 · start 2014-05

    Registered record
    Registry ID
    NCT02474914
    Conditions
    Periampullary Carcinoma Resectable
    Interventions
    Octreotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2017-04
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriampullary Carcinoma Resectable
    InterventionOctreotide; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Phase II Study With ITF2984 in Acromegalic Patients

    NCT02111044 · start 2014-04

    Registered record
    Registry ID
    NCT02111044
    Conditions
    Acromegaly
    Interventions
    Octreotide; ITF2984 500 mcg; ITF2984 1000 mcg; ITF2984 2000 mcg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionOctreotide; ITF2984 500 mcg; ITF2984 1000 mcg; ITF2984 2000 mcg
    PhasePhase 2
    Registry statusCompleted

  • Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

    NCT02019706 · start 2014-02-12

    Registered record
    Registry ID
    NCT02019706
    Conditions
    ACTH; Cushing's Syndrome
    Interventions
    DOTATATE PET-CT; F-DOPA PET CT; CT scan; Routine MRI scan; Gated MRI scan; 68Ga-DOTATATE; 18F-DOPA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-02-12
    Completion
    2030-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionACTH; Cushing's Syndrome
    InterventionDOTATATE PET-CT; F-DOPA PET CT; CT scan; Routine MRI scan +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer

    NCT02385617 · start 2014-01

    Registered record
    Registry ID
    NCT02385617
    Conditions
    Esophageal Neoplasms; Stomach Neoplasms; Weight Loss; Malnutrition
    Interventions
    Octreotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-01
    Completion
    2017-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Neoplasms; Stomach Neoplasms; Weight Loss; Malnutrition
    InterventionOctreotide; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

    NCT01869725 · start 2013-04-01

    Registered record
    Registry ID
    NCT01869725
    Conditions
    Adult Medulloblastoma; Childhood Medulloblastoma; Neuroblastoma; Neuroendocrine Tumor; Somatostatinoma
    Interventions
    gallium Ga 68-edotreotide; positron emission tomography/computed tomography; indium In 111 pentetreotide; computed tomography; contrast-enhanced magnetic resonance imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04-01
    Completion
    2018-12-26
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Medulloblastoma; Childhood Medulloblastoma; Neuroblastoma; Neuroendocrine Tumor +1 more
    Interventiongallium Ga 68-edotreotide; positron emission tomography/computed tomography; indium In 111 pentetreotide; computed tomography +1 more
    PhasePhase 2
    Registry statusCompleted